FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1025-1026 September 26, 2002 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

From a historical perspective, there is perhaps no more interesting therapeutic saga than that of aspirin, which began as a folk remedy, distilled from willow bark, and became a lifesaving preventive treatment for ischemic cardiovascular disease. Aspirin primarily inhibits the cyclooxygenase (COX)-dependent synthesis of eicosanoids, which are the end products of metabolism of essential fatty acids and include prostacyclin and thromboxane A₂. Numerous studies have shown the importance of eicosanoids in preserving the dynamic balance among thrombosis, hemostasis, and the fluidity of blood.

Recently, Cheng et al.¹ presented compelling evidence that cell–cell interactions, principally between platelets and endothelial cells, . . . [Full Text of this Article]

This article has been cited by other articles:

• Jia, Z., Guo, X., Zhang, H., Wang, M.-H., Dong, Z., Yang, T. (2008). Microsomal Prostaglandin Synthase-1-Derived Prostaglandin E2 Protects Against Angiotensin II-Induced Hypertension via Inhibition of Oxidative Stress. Hypertension 52: 952-959 [Abstract] [Full Text]  
• Furie, B., Furie, B. C. (2008). Mechanisms of Thrombus Formation. NEJM 359: 938-949 [Full Text]  
• Alberts, D. S., Potter, J. D., Martinez, M. E., Hess, L. M., Stopeck, A., Lance, P. (2005). What Happened to the Coxibs on the Way to the Cardiologist?. Cancer Epidemiol. Biomarkers Prev. 14: 555-556 [Full Text]  
• Chang, I. J., Harris, R. C. (2005). Are All COX-2 Inhibitors Created Equal?. Hypertension 45: 178-180 [Full Text]  
• Chiang, N., Bermudez, E. A., Ridker, P. M., Hurwitz, S., Serhan, C. N. (2004). Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA 101: 15178-15183 [Abstract] [Full Text]  
• Dai, W., Kloner, R. A. (2004). Relationship Between Cyclooxygenase-2 Inhibition and Thrombogenesis. J CARDIOVASC PHARMACOL THER 9: 51-59 [Abstract]  
• Hankey, G. J., Eikelboom, J. W. (2003). Cyclooxygenase-2 Inhibitors: Are They Really Atherothrombotic, and If Not, Why Not?. Stroke 34: 2736-2740 [Abstract] [Full Text]  
• Serhan, C. N., Levy, B. (2003). Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics. Proc. Natl. Acad. Sci. USA 100: 8609-8611 [Full Text]